These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19275565)

  • 1. Early toxicity screening and selection of lead compounds for parasitic diseases.
    Nogueira RC; Oliveira-Costa JF; de Sá MS; dos Santos RR; Soares MB
    Curr Drug Targets; 2009 Mar; 10(3):291-8. PubMed ID: 19275565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target assessment for antiparasitic drug discovery.
    Frearson JA; Wyatt PG; Gilbert IH; Fairlamb AH
    Trends Parasitol; 2007 Dec; 23(12):589-95. PubMed ID: 17962072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrocyclic lactones in antiparasitic therapy. Editorial.
    González-Canga A
    Curr Pharm Biotechnol; 2012 May; 13(6):851-2. PubMed ID: 22587602
    [No Abstract]   [Full Text] [Related]  

  • 4. Structure-Based Targeting of Orthologous Pathogen Proteins Accelerates Antiparasitic Drug Discovery.
    Jain V; Sharma A; Singh G; Yogavel M; Sharma A
    ACS Infect Dis; 2017 Apr; 3(4):281-292. PubMed ID: 28195698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modern approaches in the search for new lead antiparasitic compounds from higher plants.
    Queiroz EF; Wolfender JL; Hostettmann K
    Curr Drug Targets; 2009 Mar; 10(3):202-11. PubMed ID: 19275557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New technologies and screening strategies for hepatotoxicity: use of in vitro models.
    Dambach DM; Andrews BA; Moulin F
    Toxicol Pathol; 2005; 33(1):17-26. PubMed ID: 15805052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiparasitic drugs for paediatrics: systematic review, formulations, pharmacokinetics, safety, efficacy and implications for control.
    Keiser J; Ingram K; Utzinger J
    Parasitology; 2011 Oct; 138(12):1620-32. PubMed ID: 21349223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of potential hepatotoxicity induced by drugs.
    Gómez-Lechón MJ; Lahoz A; Gombau L; Castell JV; Donato MT
    Curr Pharm Des; 2010 Jun; 16(17):1963-77. PubMed ID: 20236064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Drug-Induced Liver Injury in Micropatterned Co-cultures Containing iPSC-Derived Human Hepatocytes.
    Ware BR; Berger DR; Khetani SR
    Toxicol Sci; 2015 Jun; 145(2):252-62. PubMed ID: 25716675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug discovery for parasitic diseases: powered by technology, enabled by pharmacology, informed by clinical science.
    Rao SPS; Manjunatha UH; Mikolajczak S; Ashigbie PG; Diagana TT
    Trends Parasitol; 2023 Apr; 39(4):260-271. PubMed ID: 36803572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Inhibitors as Antiparasitic Drugs: Pharmacological, Biochemical and Molecular Perspectives.
    Mukherjee S; Mukherjee N; Gayen P; Roy P; Babu SP
    Curr Drug Metab; 2016; 17(10):937-970. PubMed ID: 27719626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs.
    Kayser O; Olbrich C; Croft SL; Kiderlen AF
    Parasitol Res; 2003 Jun; 90 Suppl 2():S63-70. PubMed ID: 12937968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated dataset of screening hits against multiple neglected disease pathogens.
    Nwaka S; Besson D; Ramirez B; Maes L; Matheeussen A; Bickle Q; Mansour NR; Yousif F; Townson S; Gokool S; Cho-Ngwa F; Samje M; Misra-Bhattacharya S; Murthy PK; Fakorede F; Paris JM; Yeates C; Ridley R; Van Voorhis WC; Geary T
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1412. PubMed ID: 22247786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.
    Borsari C; Santarem N; Torrado J; Olías AI; Corral MJ; Baptista C; Gul S; Wolf M; Kuzikov M; Ellinger B; Witt G; Gribbon P; Reinshagen J; Linciano P; Tait A; Costantino L; Freitas-Junior LH; Moraes CB; Bruno Dos Santos P; Alcântara LM; Franco CH; Bertolacini CD; Fontana V; Tejera Nevado P; Clos J; Alunda JM; Cordeiro-da-Silva A; Ferrari S; Costi MP
    Eur J Med Chem; 2017 Jan; 126():1129-1135. PubMed ID: 28064141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico pharmacology for a multidisciplinary drug discovery process.
    Ortega SS; Cara LC; Salvador MK
    Drug Metabol Drug Interact; 2012; 27(4):199-207. PubMed ID: 23152402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in the development of peroxide-based anti-parasitic agents.
    Muraleedharan KM; Avery MA
    Drug Discov Today; 2009 Aug; 14(15-16):793-803. PubMed ID: 19477287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knowledge-based approaches in the design and selection of compound libraries for drug discovery.
    Viswanadhan VN; Balan C; Hulme C; Cheetham JC; Sun Y
    Curr Opin Drug Discov Devel; 2002 May; 5(3):400-6. PubMed ID: 12058615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting drugs and proteins in parasite infections with topological indices of complex networks: theoretical backgrounds, applications, and legal issues.
    González-Díaz H; Romaris F; Duardo-Sanchez A; Pérez-Montoto LG; Prado-Prado F; Patlewicz G; Ubeira FM
    Curr Pharm Des; 2010; 16(24):2737-64. PubMed ID: 20642428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.